Amprion Launches SAAmplify®-αSYN Plus: The First & Only Commercially Available CSF Test to Detect Alpha-Synuclein Profile for Multiple System Atrophy

Amprion launched SAAmplify®-αSYN Plus, described as the first and only commercially available cerebrospinal fluid test designed to detect an alpha-synuclein profile for multiple system atrophy. The diagnostic product launch could support improved identification of the rare neurodegenerative disorder, but the release provides no financial figures, clinical-performance data, or revenue outlook.